Both letermovir & maribavir can be perpetrator or victim of a drug–drug interaction
🆕️🔥 #CPK
Drug–Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir & Maribavir: Guidance for Clinicians #idsky
✨️tables✨️ #bookmark
link.springer.com/article/10.1...
🆕️🔥 #CPK
Drug–Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir & Maribavir: Guidance for Clinicians #idsky
✨️tables✨️ #bookmark
link.springer.com/article/10.1...
Drug–Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir and Maribavir: Guidance for Clinicians - Clinical Pharmacokinetics
Letermovir and maribavir have demonstrated efficacy in the prevention and treatment, respectively, of immunosuppressed patients with cytomegalovirus (CMV) infection and disease. These patients often h...
link.springer.com
November 15, 2024 at 3:54 PM
Both letermovir & maribavir can be perpetrator or victim of a drug–drug interaction
🆕️🔥 #CPK
Drug–Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir & Maribavir: Guidance for Clinicians #idsky
✨️tables✨️ #bookmark
link.springer.com/article/10.1...
🆕️🔥 #CPK
Drug–Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir & Maribavir: Guidance for Clinicians #idsky
✨️tables✨️ #bookmark
link.springer.com/article/10.1...
CMV-specific cell-mediated immunity for prediction of post-prophylaxis CMV disease in a phase 3 trial of letermovir vs valganciclovir prophylaxis in D+/R- kidney transplant recipients
TLDR: CMV CMI assay at end of ppx did NOT predict subsequent CMV disease
academic.oup.com/cid/advance-... #TxID
TLDR: CMV CMI assay at end of ppx did NOT predict subsequent CMV disease
academic.oup.com/cid/advance-... #TxID
Cytomegalovirus-specific cell-mediated immunity for prediction of post-prophylaxis CMV disease in a phase 3 trial of letermovir vs valganciclovir prophylaxis in donor CMV-seropositive recipient CMV-se...
Among adult cytomegalovirus (CMV) donor-seropositive/recipient-seronegative kidney transplant recipients who received antiviral prophylaxis with letermovir
academic.oup.com
December 1, 2025 at 1:58 PM
CMV-specific cell-mediated immunity for prediction of post-prophylaxis CMV disease in a phase 3 trial of letermovir vs valganciclovir prophylaxis in D+/R- kidney transplant recipients
TLDR: CMV CMI assay at end of ppx did NOT predict subsequent CMV disease
academic.oup.com/cid/advance-... #TxID
TLDR: CMV CMI assay at end of ppx did NOT predict subsequent CMV disease
academic.oup.com/cid/advance-... #TxID
Letermovir prophylaxis guided by cytomegalovirus cell-mediated immunity improves the outcomes of allogeneic hematopoietic stem cell transplant recipients
✅ Just Accepted
#IDSky
✅ Just Accepted
#IDSky
Letermovir prophylaxis guided by cytomegalovirus cell-mediated immunity improves the outcomes of allogeneic hematopoietic stem cell transplant recipients
The control of cytomegalovirus (CMV) reactivation after allogeneic hematopoietic stem cell transplantation (allo-HSCT) depends heavily on the reconstitution of CMV-specific cell-mediated immunity (CMI).
doi.org
July 30, 2025 at 6:58 PM
Letermovir prophylaxis guided by cytomegalovirus cell-mediated immunity improves the outcomes of allogeneic hematopoietic stem cell transplant recipients
✅ Just Accepted
#IDSky
✅ Just Accepted
#IDSky
Interesting study re viral persistence. HIV+ people taking letermovir for CMV suppression showed improvement in CD4 cell count & CD4/CD8 ratio, esp women. Sara Gianelle Weibel calls it “most exciting intervention done in people with HIV for inflammation & aging in last 20 years.” #CROI2025
March 12, 2025 at 6:41 PM
Interesting study re viral persistence. HIV+ people taking letermovir for CMV suppression showed improvement in CD4 cell count & CD4/CD8 ratio, esp women. Sara Gianelle Weibel calls it “most exciting intervention done in people with HIV for inflammation & aging in last 20 years.” #CROI2025
The aim of this review was to summarize the pharmacokinetic and drug–drug interaction profile of the recently introduced CMV agents letermovir and maribavir #idsky #bookmark #TxID
Both letermovir & maribavir can be perpetrator or victim of a drug–drug interaction
🆕️🔥 #CPK
Drug–Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir & Maribavir: Guidance for Clinicians #idsky
✨️tables✨️ #bookmark
link.springer.com/article/10.1...
🆕️🔥 #CPK
Drug–Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir & Maribavir: Guidance for Clinicians #idsky
✨️tables✨️ #bookmark
link.springer.com/article/10.1...
Drug–Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir and Maribavir: Guidance for Clinicians - Clinical Pharmacokinetics
Letermovir and maribavir have demonstrated efficacy in the prevention and treatment, respectively, of immunosuppressed patients with cytomegalovirus (CMV) infection and disease. These patients often h...
link.springer.com
November 16, 2024 at 8:49 PM
The changing impact of human Cytomegalovirus serology and infection on patient outcome after allogeneic hematopoietic stem cell transplantation: an Italian prospective multicenter survey in the era of letermovir prophylaxis.
✅ Just Accepted
#IDSky
✅ Just Accepted
#IDSky
The changing impact of human Cytomegalovirus serology and infection on patient outcome after allogeneic hematopoietic stem cell transplantation: an Italian prospective multicenter survey in the era of letermovir prophylaxis.
In the letermovir-primary-prophylaxis (LET-PP) era the epidemiology of human-cytomegalovirus-infections (HCMV-i) in allogeneic hematopoietic-stem-cell-transplant (allo-HSCT) has changed.
doi.org
April 26, 2025 at 2:33 PM
The changing impact of human Cytomegalovirus serology and infection on patient outcome after allogeneic hematopoietic stem cell transplantation: an Italian prospective multicenter survey in the era of letermovir prophylaxis.
✅ Just Accepted
#IDSky
✅ Just Accepted
#IDSky
The role of CMV-specific cellular immunity in transplant recipients with letermovir prophylaxis: to be determined
✅ Just Accepted
🔗 https://bit.ly/4oqR2dv
✅ Just Accepted
🔗 https://bit.ly/4oqR2dv
December 5, 2025 at 6:30 PM
The role of CMV-specific cellular immunity in transplant recipients with letermovir prophylaxis: to be determined
✅ Just Accepted
🔗 https://bit.ly/4oqR2dv
✅ Just Accepted
🔗 https://bit.ly/4oqR2dv
Asymptomatic CMV Suppression with Letermovir Improves Immunologic and Functional Aging-related Outcomes in Treated HIV
Letermovir significantly increased CD4 counts, especially in women and those with persistently low CD4 T cells, improved CD4/CD8 ratio and physical function
Letermovir significantly increased CD4 counts, especially in women and those with persistently low CD4 T cells, improved CD4/CD8 ratio and physical function
ACTG Presents Study at CROI Demonstrating Potential of CMV-specific Antiviral Inhibitor to Improve Aging-Related Outcomes among People Living with HIV and CMV (Cytomegalovirus)
ACTG Presents Study at CROI Demonstrating Potential of CMV-specific Antiviral Inhibitor to Improve Aging-Related Outcomes among People Living with HIV ...
www.globenewswire.com
March 12, 2025 at 10:48 PM
Asymptomatic CMV Suppression with Letermovir Improves Immunologic and Functional Aging-related Outcomes in Treated HIV
Letermovir significantly increased CD4 counts, especially in women and those with persistently low CD4 T cells, improved CD4/CD8 ratio and physical function
Letermovir significantly increased CD4 counts, especially in women and those with persistently low CD4 T cells, improved CD4/CD8 ratio and physical function
Most recently (#CROI2025), ACTG 5383 showed that treating latent cytomegalovirus (CMV) infection with letermovir led to reduced inflammation & improvements in immune function & physical function. Over 1/2 of HIV+ people in US are 50+, so interventions for aging are increasingly important. 5/
CMV Treatment May Reduce Inflammation and Improve Immune Function
The cytomegalovirus antiviral drug letermovir led to improvements in immune biomarkers and physical function in people with HIV.
www.poz.com
April 10, 2025 at 2:52 PM
Most recently (#CROI2025), ACTG 5383 showed that treating latent cytomegalovirus (CMV) infection with letermovir led to reduced inflammation & improvements in immune function & physical function. Over 1/2 of HIV+ people in US are 50+, so interventions for aging are increasingly important. 5/
Most HIV research has focused on antiretrovirals, but good to see more attention to therapies for chronic illness (eg, GLP-1 meds, letermovir). Shifting NIH funding from infectious diseases to chronic conditions may sound like loss for people with HIV, but they also stand to benefit! #CROI2025
March 12, 2025 at 7:12 PM
Most HIV research has focused on antiretrovirals, but good to see more attention to therapies for chronic illness (eg, GLP-1 meds, letermovir). Shifting NIH funding from infectious diseases to chronic conditions may sound like loss for people with HIV, but they also stand to benefit! #CROI2025
Letermovir, an antiviral drug for cytomegalovirus (CMV), was associated with reduced inflammation, improved CD4 T-cell counts & CD4/CD8 ratios & better physical function among people with HIV, according to a study presented at #CROI2025.
CMV Treatment May Reduce Inflammation and Improve Immune Function
The cytomegalovirus antiviral drug letermovir led to improvements in immune biomarkers and physical function in people with HIV.
www.poz.com
March 25, 2025 at 4:12 PM
Letermovir, an antiviral drug for cytomegalovirus (CMV), was associated with reduced inflammation, improved CD4 T-cell counts & CD4/CD8 ratios & better physical function among people with HIV, according to a study presented at #CROI2025.
#CROI2025 Letermovir, an antiviral drug for cytomegalovirus (CMV), was associated with reduced inflammation, improved CD4/CD8 T-cell ratios & better physical function for people with HIV on effective ART, according to a study presented at CROI
www.aidsmap.com/news/mar-202...
www.aidsmap.com/news/mar-202...
CMV antiviral may reduce inflammation and improve immune function in people with HIV
Letermovir, an antiviral drug for cytomegalovirus (CMV), was associated with reduced inflammation, improved CD4/CD8 T-cell ratios and better physical function for people with HIV on effective antiretr...
www.aidsmap.com
March 21, 2025 at 5:51 PM
#CROI2025 Letermovir, an antiviral drug for cytomegalovirus (CMV), was associated with reduced inflammation, improved CD4/CD8 T-cell ratios & better physical function for people with HIV on effective ART, according to a study presented at CROI
www.aidsmap.com/news/mar-202...
www.aidsmap.com/news/mar-202...
Above EC50, Below Certainty: Protein Binding and Timing Assumptions in Maternal?Fetal Letermovir Translation
✅ Just Accepted
🔗 https://bit.ly/4c9K4Xj
✅ Just Accepted
🔗 https://bit.ly/4c9K4Xj
April 14, 2026 at 3:21 AM
Above EC50, Below Certainty: Protein Binding and Timing Assumptions in Maternal?Fetal Letermovir Translation
✅ Just Accepted
🔗 https://bit.ly/4c9K4Xj
✅ Just Accepted
🔗 https://bit.ly/4c9K4Xj
Dr. Danniel Zamora of Fred Hutch with a great overview of advances in CMV in alloSCT and CAR-T for KUMC’s annual Advances in the Treatment of Hematologic Malignancies and Cellular Therapeutics Symposium. Doing some interesting work with CMV CMI and duration of letermovir ppx!! #IDSky
April 19, 2025 at 6:54 PM
Dr. Danniel Zamora of Fred Hutch with a great overview of advances in CMV in alloSCT and CAR-T for KUMC’s annual Advances in the Treatment of Hematologic Malignancies and Cellular Therapeutics Symposium. Doing some interesting work with CMV CMI and duration of letermovir ppx!! #IDSky
#IDSky #PharmSky #TransplantIDSky @idsainfo.bsky.social @cidjournal.bsky.social @ofidjournal.bsky.social @sidpharm.bsky.social
Which of the CMV antiviral resistance mutations would affect Letermovir?
A. UL51
B. UL54
C. UL56
D. UL97
Which of the CMV antiviral resistance mutations would affect Letermovir?
A. UL51
B. UL54
C. UL56
D. UL97
January 25, 2025 at 1:45 PM
#IDSky #PharmSky #TransplantIDSky @idsainfo.bsky.social @cidjournal.bsky.social @ofidjournal.bsky.social @sidpharm.bsky.social
Which of the CMV antiviral resistance mutations would affect Letermovir?
A. UL51
B. UL54
C. UL56
D. UL97
Which of the CMV antiviral resistance mutations would affect Letermovir?
A. UL51
B. UL54
C. UL56
D. UL97
💊 Letermovir vs valganciclovir: a promising alternative for CMV prophylaxis! #TXPforAll #Transplantation #OpenAccess tinyurl.com/bdzb4xvr
September 22, 2026 at 12:00 PM
💊 Letermovir vs valganciclovir: a promising alternative for CMV prophylaxis! #TXPforAll #Transplantation #OpenAccess tinyurl.com/bdzb4xvr
Utility of quantiferron-CMV testing after completion of letermovir-prophylaxis post-HCT… test performance suboptimal #IDSky
academic.oup.com/cid/advance-...
academic.oup.com/cid/advance-...
An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic ...
AbstractBackground. Cytomegalovirus (CMV)-specific cell-mediated immunity (CMV-CMI) prevents CMV reactivation after hematopoietic cell transplant (HCT). Tr
academic.oup.com
December 10, 2025 at 2:13 PM
Utility of quantiferron-CMV testing after completion of letermovir-prophylaxis post-HCT… test performance suboptimal #IDSky
academic.oup.com/cid/advance-...
academic.oup.com/cid/advance-...
How about after stem cell transplant?
An Analysis of CMV-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in CMV-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant
Similarly unhelpful
academic.oup.com/cid/advance-...
An Analysis of CMV-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in CMV-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant
Similarly unhelpful
academic.oup.com/cid/advance-...
December 1, 2025 at 2:13 PM
How about after stem cell transplant?
An Analysis of CMV-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in CMV-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant
Similarly unhelpful
academic.oup.com/cid/advance-...
An Analysis of CMV-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in CMV-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant
Similarly unhelpful
academic.oup.com/cid/advance-...
From @astct.bsky.social TCT Journal
#Letermovir ppx in allo-HSCT tx #alemtuzumab in first 100 days
- 🔽 CMV
- 🔽 chronic GVHD
- ↔️ acute GVHD
- ↔️ ☠️
Added by Aneela Majid @clevelandclinic.bsky.social
https://buff.ly/4fUHFhX
#Letermovir ppx in allo-HSCT tx #alemtuzumab in first 100 days
- 🔽 CMV
- 🔽 chronic GVHD
- ↔️ acute GVHD
- ↔️ ☠️
Added by Aneela Majid @clevelandclinic.bsky.social
https://buff.ly/4fUHFhX
transplantid.net
January 16, 2025 at 5:15 PM
From @astct.bsky.social TCT Journal
#Letermovir ppx in allo-HSCT tx #alemtuzumab in first 100 days
- 🔽 CMV
- 🔽 chronic GVHD
- ↔️ acute GVHD
- ↔️ ☠️
Added by Aneela Majid @clevelandclinic.bsky.social
https://buff.ly/4fUHFhX
#Letermovir ppx in allo-HSCT tx #alemtuzumab in first 100 days
- 🔽 CMV
- 🔽 chronic GVHD
- ↔️ acute GVHD
- ↔️ ☠️
Added by Aneela Majid @clevelandclinic.bsky.social
https://buff.ly/4fUHFhX
🆕 From the #StemCellEvidence alert:
📑 Letermovir prophylaxis timing in standard-risk and very high-risk adult CMV-seropositive allogeneic hematopoietic stem cell transplant recipients: A systematic literature review
by Wang et al.
🔗 Link in the comments
#MedSky
📑 Letermovir prophylaxis timing in standard-risk and very high-risk adult CMV-seropositive allogeneic hematopoietic stem cell transplant recipients: A systematic literature review
by Wang et al.
🔗 Link in the comments
#MedSky
July 13, 2026 at 11:21 AM
🆕 From the #StemCellEvidence alert:
📑 Letermovir prophylaxis timing in standard-risk and very high-risk adult CMV-seropositive allogeneic hematopoietic stem cell transplant recipients: A systematic literature review
by Wang et al.
🔗 Link in the comments
#MedSky
📑 Letermovir prophylaxis timing in standard-risk and very high-risk adult CMV-seropositive allogeneic hematopoietic stem cell transplant recipients: A systematic literature review
by Wang et al.
🔗 Link in the comments
#MedSky
FDA recently approved Merck Research Laboratories, Rahway, NJ's letermovir (Prevymis) a new CMV antiviral for prophylaxis in high-risk kidney transplant populations. Letermovir prophylaxis was not associated with the development of resistance, supporting its use. academic.oup.com/jid/article/...
Cytomegalovirus Antiviral Resistance Among Kidney Transplant Recipients in a Phase 3 Trial of Letermovir vs Valganciclovir Prophylaxis
In a trial of cytomegalovirus prophylaxis with letermovir or valganciclovir for up to 200 days in 589 cytomegalovirus-seronegative kidney transplant recipi
academic.oup.com
December 18, 2024 at 11:10 PM
FDA recently approved Merck Research Laboratories, Rahway, NJ's letermovir (Prevymis) a new CMV antiviral for prophylaxis in high-risk kidney transplant populations. Letermovir prophylaxis was not associated with the development of resistance, supporting its use. academic.oup.com/jid/article/...
#idboardreview 50 M environmental inspector CML s/p allogeneic-HSCT, ppx: acyclovir, letermovir, inhaled AmB, fluconazole: fever/ginginval pain 1 wk postT: facial pain, necrotic gum, CT phlegmon in cervicofacial s/p I&D septate, branched hyphae w/tissue invasion #idsky #idmeded
January 14, 2026 at 11:08 PM
#idboardreview 50 M environmental inspector CML s/p allogeneic-HSCT, ppx: acyclovir, letermovir, inhaled AmB, fluconazole: fever/ginginval pain 1 wk postT: facial pain, necrotic gum, CT phlegmon in cervicofacial s/p I&D septate, branched hyphae w/tissue invasion #idsky #idmeded
CMV-CMI-guided letermovir prophylaxis may help reduce the risk of late-onset cs-CMVi, particularly in individuals at high risk.
#IDSky @cidjournal.bsky.social
pubmed.ncbi.nlm.nih.gov/40705849/
#IDSky @cidjournal.bsky.social
pubmed.ncbi.nlm.nih.gov/40705849/
Letermovir prophylaxis guided by cytomegalovirus cell-mediated immunity improves the outcomes of allogeneic hematopoietic stem cell transplant recipients - PubMed
CMV-CMI-guided letermovir prophylaxis may help reduce the risk of late-onset cs-CMVi, particularly in individuals at high risk.
pubmed.ncbi.nlm.nih.gov
August 4, 2025 at 1:30 PM
CMV-CMI-guided letermovir prophylaxis may help reduce the risk of late-onset cs-CMVi, particularly in individuals at high risk.
#IDSky @cidjournal.bsky.social
pubmed.ncbi.nlm.nih.gov/40705849/
#IDSky @cidjournal.bsky.social
pubmed.ncbi.nlm.nih.gov/40705849/